Intranasal glutathione - (in)GSH ( DrugBank: Glutathione )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 6 | Parkinson disease | 1 |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01398748 (ClinicalTrials.gov) | July 2012 | 19/7/2011 | Intranasal Glutathione in Parkinson's Disease | A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease | Parkinson's Disease (PD) | Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery | Bastyr University | National Center for Complementary and Integrative Health (NCCIH) | Completed | 21 Years | 100 Years | All | 34 | Phase 1 | United States |